IDYA: IDEAYA Biosciences Inc Price-to-Revenue Multiple

Symbol and logo of brand IDEAYA Biosciences Inc (IDYA)

The success of IDEAYA Biosciences (IDYA) is directly linked to the results of oncology drug trials, while capital remains stable. The price-to-sales multiple on the GURU.Markets base chart contains volatility data, where the indicator holds around 83.40. The brand is recognized as a leader in precision therapy, and drug development operational processes are fully outsourced to external contract research organizations.

IDYA IDEAYA Corp Market Cap to Revenue (07/04/2022 - 11/13/2026)

Analytical breakdowns for IDEAYA Bio (IDYA)

- share price and consensus valuation forecast:
Price Performance Chart ideayabio.com|IDYA - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization IDEAYA Bio|IDYA - Enterprise Value
- book capitalization data:
Net Asset Value per Share IDEAYA Biosciences|IDYA - Company Net Assets|Market Cap to Book Value Multiple ideayabio.com|IDYA - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital IDEAYA Biosciences|IDYA - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio IDEAYA Corp|IDYA - Company Total Debt|Debt to Net Assets Ratio IDEAYA Bio|IDYA - Company Long-Term Liabilities|Amount of Current Liabilities IDEAYA Biosciences|Intermediate Coverage Ratio ideayabio.com
- earnings and multiples data:
IDYA - Net Profit|Expected Net Profit IDEAYA Biosciences|IDYA - Price to Earnings Ratio|Future Price to Earnings Multiple IDEAYA Biosciences Inc|IDYA - PEG Multiple|EV/EBITDA Multiple IDEAYA Bio|IDYA - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months IDEAYA Biosciences|IDYA - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months ideayabio.com|IDYA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year IDEAYA Biosciences
- sales revenue and business income indicators:
IDYA - Revenue and Sales Volume|Company Revenue Forecast ideayabio.com|IDYA - P/S Multiple|Market Cap to Future Revenue Ratio IDEAYA Bio
Summary company analytics:ideayabio.com, IDYA
Mass-produced product of ideayabio.com

The global humanitarian status of IDEAYA Biosciences (IDYA) developments in targeted cancer therapy minimizes external risks, focusing investor attention on the efficiency of business capitalization. This market capitalization-to-revenue ratio daily compares the company's market value with its actual income, allowing investors to filter out market noise and determine the asset's fair value, thereby preventing an unjustified premium for future successes.

Who IDEAYA Biosciences competes with

GMAB (genmab.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EXEL (Exelixis)|Price-to-Revenue Multiple Nuvalent Inc|Kymera Therapeutics Inc - P/S Multiple|Price to Sales Enliven Corp|ORIC (ORIC Pharmaceuticals) - Market Cap to Revenue|RLAY: Market Cap to Sales Volume|NRIX (Nurix Therapeutics, Inc.) - P/S Multiple|Price to Sales Tyra Biosciences Inc TYRA|P/S Multiple VSTM|Monte Rosa Corp - Market Cap to Revenue Ratio|Cullinan Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMRX|CCCC: Market Cap to Revenue|Black Diamond Therapeutics, Inc. - Market Cap to Sales Volume|RPTX: P/S Multiple|PMV Pharmaceuticals, Inc - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales Propanc Biopharma, Inc. PPCB|Price-to-Revenue Ratio Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics, Inc.)|P/S Multiple Blueprint Medicines Corp. BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX